4.7 Review

Strategies towards safer opioid analgesics-A review of old and upcoming targets

Journal

BRITISH JOURNAL OF PHARMACOLOGY
Volume 180, Issue 7, Pages 975-993

Publisher

WILEY
DOI: 10.1111/bph.15760

Keywords

-

Ask authors/readers for more resources

This article discusses the current status of using opioids for pain treatment and some potential new targets that may lead to safer next generation analgesics.
Opioids continue to be of use for the treatment of pain. Most clinically used analgesics target the mu opioid receptor whose activation results in adverse effects like respiratory depression, addiction and abuse liability. Various approaches have been used by the field to separate receptor-mediated analgesic actions from adverse effects. These include biased agonism, opioids targeting multiple receptors, allosteric modulators, heteromers and splice variants of the mu receptor. This review will focus on the current status of the field and some upcoming targets of interest that may lead to a safer next generation of analgesics.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Chemistry, Medicinal

Potent, Efficacious, and Stable Cyclic Opioid Peptides with Long Lasting Antinociceptive Effect after Peripheral Administration

Azzurra Stefanucci, Marilisa Pia Dimmito, Giorgia Macedonio, Laura Ciarlo, Stefano Pieretti, Ettore Novellino, Wei Lei, Deborah Barlow, Karen L. Houseknecht, John M. Streicher, Adriano Mollica

JOURNAL OF MEDICINAL CHEMISTRY (2020)

Article Cell Biology

Synthesis and Characterization of Azido Aryl Analogs of IBNtxA for Radio-Photoaffinity Labeling Opioid Receptors in Cell Lines and in Mouse Brain

Steven G. Grinnell, Rajendra Uprety, Andras Varadi, Joan Subrath, Amanda Hunkele, Ying Xian Pan, Gavril W. Pasternak, Susruta Majumdar

Summary: Mu opioid receptors (MOR-1) play a crucial role in the biological effects of clinically used opioids, with the OPRM1 gene generating multiple splice variants including 6TM variants associated with the analgesic effects of novel opioids. IBNtxA has been identified as a potent analgesic with reduced side effects compared to traditional opiates, and can be used to photolabel mouse mu opioid receptors for further investigation into ligand-protein contacts and signaling complexes.

CELLULAR AND MOLECULAR NEUROBIOLOGY (2021)

Article Biochemistry & Molecular Biology

Inhibition of Hsp90 in the spinal cord enhances the antinociceptive effects of morphine by activating an ERK-RSK pathway

David Duron, Wei Lei, Natalie K. Barker, Carrie Stine, Sanket Mishra, Brian S. J. Blagg, Paul R. Langlais, John M. Streicher

SCIENCE SIGNALING (2020)

Article Biochemistry & Molecular Biology

Natural Products for the Treatment of Pain: Chemistry and Pharmacology of Salvinorin A, Mitragynine, and Collybolide

Soumen Chakraborty, Susruta Majumdar

Summary: Pain management has been a significant issue in medicine, with efforts focused on developing alternative opioids without side effects.

BIOCHEMISTRY (2021)

Article Behavioral Sciences

Use of home cage wheel running to assess the behavioural effects of administering a mu/delta opioid receptor heterodimer antagonist for spontaneous morphine withdrawal in the rat

Michael M. Morgan, Danielle L. Peecher, John M. Streicher

Summary: This study evaluated a novel antagonist (D24M) of the mu-/delta-opioid receptor (MOR/DOR) heterodimer in male rats. The results showed that D24M did not have disruptive side effects and tended to prolong morphine's antinociceptive effects in non-tolerant rats. Further studies are needed to assess the effects of D24M on withdrawal to continuous morphine administration in rats with persistent pain.

BEHAVIOURAL BRAIN RESEARCH (2021)

Article Cell Biology

Kratom Alkaloids, Natural and Semi-Synthetic, Show Less Physical Dependence and Ameliorate Opioid Withdrawal

Lisa L. Wilson, Soumen Chakraborty, Shainnel O. Eans, Thomas J. Cirino, Heather M. Stacy, Chloe A. Simons, Rajendra Uprety, Susruta Majumdar, Jay P. McLaughlin

Summary: The study confirmed the medicinal value of Thai traditional tea kratom, showing that kratom and its alkaloids can reduce dependence on opioids and alleviate withdrawal symptoms.

CELLULAR AND MOLECULAR NEUROBIOLOGY (2021)

Article Multidisciplinary Sciences

Cannabis sativa terpenes are cannabimimetic and selectively enhance cannabinoid activity

Justin E. LaVigne, Ryan Hecksel, Attila Keresztes, John M. Streicher

Summary: Limited evidence suggests that terpenes found in Cannabis sativa may have cannabimimetic activity and can enhance cannabinoid activity. These multifunctional cannabimimetic ligands provide support for the entourage effect hypothesis, potentially enhancing the therapeutic properties of cannabinoids.

SCIENTIFIC REPORTS (2021)

Article Biochemistry & Molecular Biology

Discovery of Novel Delta Opioid Receptor (DOR) Inverse Agonist and Irreversible (Non-Competitive) Antagonists

Parthasaradhireddy Tanguturi, Vibha Pathak, Sixue Zhang, Omar Moukha-Chafiq, Corinne E. Augelli-Szafran, John M. Streicher

Summary: The study successfully developed novel inverse agonists and irreversible antagonists for the delta opioid receptor, providing new tools to investigate its biology or potential therapeutics.

MOLECULES (2021)

Review Biochemistry & Molecular Biology

Alternative Pre-mRNA Splicing of the Mu Opioid Receptor Gene, OPRM1: Insight into Complex Mu Opioid Actions

Shan Liu, Wen-Jia Kang, Anna Abrimian, Jin Xu, Luca Cartegni, Susruta Majumdar, Patrick Hesketh, Alex Bekker, Ying-Xian Pan

Summary: The OPRM1 gene undergoes extensive alternative splicing to produce multiple splice variants with important pharmacological implications for the actions of opioid drugs. These variants can mediate distinct effects of various mu opioids and be targeted for the development of novel analgesics with potent efficacy against multiple types of pain while reducing side effects associated with traditional opiates.

BIOMOLECULES (2021)

Correction Biochemistry & Molecular Biology

Discovery of Novel Delta Opioid Receptor (DOR) Inverse Agonist and Irreversible (Non-Competitive) Antagonists (vol 26, 6693, 2021)

Parthasaradhireddy Tanguturi, Vibha Pathak, Sixue Zhang, Omar Moukha-Chafiq, Corinne E. Augelli-Szafran, John M. Streicher

MOLECULES (2022)

Article Pharmacology & Pharmacy

Extracellular Alterations in pH and K plus Modify the Murine Brain Endothelial Cell Total and Phospho-Proteome

Jared R. Wahl, Anjali Vivek, Seph M. Palomino, Moyad Almuslim, Karissa E. Cottier, Paul R. Langlais, John M. Streicher, Todd W. Vanderah, Erika Liktor-Busa, Tally M. Largent-Milnes

Summary: This study investigates the role of cortical spreading depression (CSD) in blood-brain barrier (BBB) pathology using an in vitro model. The findings suggest that CSD can lead to relocalization and functional alteration of proteins associated with the actin cytoskeleton and endothelial tight junctions. Additionally, unique phosphorylation signatures were identified in phospho-proteomic analysis, highlighting Zona Occludins 1 (ZO-1) as a potential pathologic checkpoint of the BBB.

PHARMACEUTICS (2022)

Article Pharmacology & Pharmacy

Inhibition of HSP90 Preserves Blood-Brain Barrier Integrity after Cortical Spreading Depression

Seph M. Palomino, Aidan A. Levine, Jared Wahl, Erika Liktor-Busa, John M. Streicher, Tally M. Largent-Milnes

Summary: This study investigated the role of heat shock protein HSP90 in blood-brain barrier leak associated with cortical spreading depression (CSD). The results showed that inhibition of HSP90 reduced CSD-induced blood-brain barrier leak, suggesting a potential therapeutic approach for headache disorders targeting HSP90.

PHARMACEUTICS (2022)

Article Biochemistry & Molecular Biology

HSP90 inhibition in the mouse spinal cord enhances opioid signaling by suppressing an AMPK-mediated negative feedback loop

Katherin A. Gabriel, John M. Streicher

Summary: Opioids are effective for acute pain but chronic use leads to tolerance. Inhibiting the chaperone protein HSP90 increases the antinociceptive effects of opioids by activating the kinase ERK. This activation is mediated by the relief of a negative feedback loop involving the kinase AMPK.

SCIENCE SIGNALING (2023)

No Data Available